# Dry mouth from radioactive iodine, PSMA radioligand therapy and cancer drugs

Source: https://onco.cc/protocols/dry-mouth-from-cancer-drugs-and-radionuclide-therapy/  
OnCo record `dry-mouth-from-cancer-drugs-and-radionuclide-therapy` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Some cancer treatments reduce saliva: radioactive iodine, lutetium-177 PSMA therapy and some tablets. Sips of water, sugar-free gum and saliva sprays or gels can ease it, and less saliva means more tooth decay, so dental care matters. Tell your team if it is hard to eat or talk, or your mouth is sore or has white patches. Your own team's advice comes first.

## Summary

This page covers dry mouth from radioactive iodine (I-131), PSMA radioligand therapy, futibatinib and selpercatinib. It is for understanding care; the treating team's own protocol comes first. Frequency, from the labels: lutetium-177 vipivotide tetraxetan 46% in the pooled US safety population (N = 1320; 61% in PSMAfore, 39% in VISION) and 39.3% in the EU SmPC (VISION); futibatinib 35% (US label, 103 patients, no grade 3) and 31.0% (EU SmPC); selpercatinib 44%, 39% and 32% across LIBRETTO-001, -431 and -531 (US label), very common in the EU SmPC. The US sodium iodide I 131 label lists sialadenitis and xerostomia as radiation toxicities; the ATA (2025) cites acute salivary side effects in 39% of 262 patients in the first year after ablation.

Prevention. For radioiodine the ATA recommends counselling and general measures including hydration (both Good Practice Statements) and calls the role of sour sweets and other sialagogues uncertain, with evidence insufficient to recommend for or against hydration, sour candies, amifostine or cholinergic agents as gland protection. The US label, by contrast, advises good hydration for one week and a sialagogue. A 2026 systematic review of sialagogue timing (three observational studies, 818 adults) could make no definitive recommendation. For lutetium-177 PSMA therapy the EANM/SNMMI guideline (2023) gives no general recommendation on drugs to reduce salivary uptake; a full-text review and the one ice-pack study read found cooling of limited or doubtful value.

Dose rules. Only lutetium-177 vipivotide tetraxetan has a dry mouth rule, and the labels differ: the US label withholds at grade 2 or 3 and stops for good if grade 3 recurs after one reduction; the EU SmPC lists a 20% reduction at grade 3 only. Futibatinib and selpercatinib fall under each label's general rule for other grade 3 or 4 reactions.

Relief. The ISOO/MASCC/ASCO guideline (2021) says topical lubricants or saliva substitutes may be offered for xerostomia from nonsurgical cancer therapies (evidence quality intermediate, strength strong), and sugar-free lozenges or gum (intermediate, moderate). Its pilocarpine and cevimeline recommendation is for dry mouth after head and neck radiotherapy only. For PSMA therapy the EANM/SNMMI guideline says pilocarpine must be weighed for the individual because benefits and risks could be closely balanced, and that sialendoscopy may help unacceptable xerostomia (weak). The MASCC/ISOO statement (2024, expert opinion) adds a medicines review, dental care two to four times a year, fluoride, and antifungal treatment for clinical oral candidiasis. No guideline read addresses dry mouth from kinase inhibitors, or from actinium-225 PSMA agents, which are investigational.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: xerostomia; salivary gland hypofunction; dry mouth on Pluvicto; dry mouth after radioiodine; radioiodine sialadenitis; swollen salivary glands after radioactive iodine; dry mouth on selpercatinib; dry mouth on futibatinib; hyposalivation

## Connected records

- protocols: [Blood count, kidney and liver monitoring during lutetium-177 radioligand therapy](https://onco.cc/protocols/blood-count-and-kidney-monitoring-during-radioligand-therapy/), [Dental assessment before head and neck radiotherapy and osteoradionecrosis prevention](https://onco.cc/protocols/head-and-neck-radiotherapy-dental-assessment-osteoradionecrosis/), [Mouth care and oral mucositis prevention during head and neck radiotherapy](https://onco.cc/protocols/head-and-neck-radiotherapy-oral-mucositis/), [Oral care and oral mucositis prevention during cancer treatment](https://onco.cc/protocols/oral-mucositis-prevention-and-oral-care/), [Radiation safety at home after lutetium-177 PSMA or dotatate therapy](https://onco.cc/protocols/lutetium-177-therapy-home-radiation-safety/), [Radiation safety at home after radioactive iodine (I-131) for thyroid cancer](https://onco.cc/protocols/radioiodine-therapy-home-radiation-safety/), [Taste changes (dysgeusia) during cancer treatment](https://onco.cc/protocols/taste-changes-during-cancer-treatment/)
- technologies: [Dry mouth, teeth and taste after head and neck radiotherapy](https://onco.cc/technologies/dry-mouth-teeth-after-head-neck-radiotherapy/), [Lutetium-177 radioligand therapy](https://onco.cc/technologies/lu177-radioligand-therapy/), [Radioiodine therapy and whole-body iodine scanning](https://onco.cc/technologies/radioiodine-therapy/)
- drugs: [Actinium-225 PSMA agents](https://onco.cc/drugs/ac225-psma/), [Futibatinib](https://onco.cc/drugs/futibatinib/), [Lutetium-177 vipivotide tetraxetan](https://onco.cc/drugs/pluvicto/), [Pilocarpine](https://onco.cc/drugs/pilocarpine/), [Radioactive iodine (I-131)](https://onco.cc/drugs/radioactive-iodine/), [Selpercatinib](https://onco.cc/drugs/selpercatinib/)
- terms: [Radioiodine therapy (I-131)](https://onco.cc/terms/radioiodine-term/)

---
JSON: https://onco.cc/api/v1/entities/dry-mouth-from-cancer-drugs-and-radionuclide-therapy.json